Minimal Phototoxic Doses and 8-MOP Plasma Levels in PUVA Patients  by Goldstein, David P. et al.
0022-202X/82/7805-0429$02.00/ 0 
THE JOURNAL OF INVESTIGATIVE D E RMATOLOG Y, 78:429-433, 1982 
Copyright © 1982 by The Williams & Wilkins Co. 
Vol. 78, No. 5 
Printed in U.S.A. 
Minimal Phototoxic Doses and 8-MOP Plasma Levels in PUV A Patients 
DAVID P_ GOLDSTEIN, B.A., D_ MARTIN CARTER, M_D_, PH_D_, Bo LJUNGGREN, M_D" AND 
JUDITH BURKHOLDER, RN., M.8_N_ 
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, U.S.A. 
We have simultaneously measured plasma levels of 8-
Dlethoxypsoralen (8-MOP) and photosensitivity to long-
wave ultraviolet irradiation (UV-A) over a time scale 
from 1-8 hr in 20 nonfasting volunteers undergoing pho-
to chemotherapy for psoriasis with 8-MOP and UV-A 
(PUV A). Five 4 cm2 patches of skin on the buttocks were 
irradiated (365 nm, 2-28 joules) with fluorescent lamps 
(Sylvania FR72T12) at each of 4 times from 2-6 hr after 
ingestion of the 8-MOP. The skin reaction was measured 
as the minimal photo toxic dose (MPD) for each of the 4 
exposures at 48 hr after irradiation. 8-MOP was ex-
tracted from plasma by the benzene extraction method 
we have previously described. 8-MOP levels were deter-
Dlined by UV absorbance after separation by high pres-
sure liquid chromatography (HPLC) in a silica particle 
column eluted with methylene chloride:acetonitrile 
(95::5). 
Two volunteers displayed unusual biphasic time-
course patterns under the nonfasting conditions. Mono-
phasic patterns were observed for both patients under 
fasting conditions. Two volunteers under fasting condi-
tions demonstrated reproducible time-course patterns 
on 4 occasions each. All subjects received approximately 
the same 8-MOP dose (mg/kg), but peak plasma levels of 
the drug varied widely from person to person, and there 
was no correlation between dose and peak plasma level. 
For each subject, however, there was a correlation be-
tween 8-MOP plasma level and MPD such that an inverse 
proportionality existed. In our population of 20 volun-
teers no erythema was observed in 4 patients whose 
peak 8-MOP plasma levels were below 30 ng/ml. In 10 
patients maximum sensitivity to irradiation occurred 
siDlultaneou sly with development of peak levels of 8-
MOP observed with time. On the average there is a 0 to 
1 hr delay between peak 8-MOP plasma concentration 
and maximum sensitivity to irradiation. In our experi-
ence we have found that knowledge of a patient's pattern 
of plasma levels of 8-MOP over time is a valuable tool 
for evaluating patients who respond poorly to PUV A 
therapy. 
Photochemotherapy with 8-methoxypsoralen (8-MOP) and 
UV -A irradiation (PUV A) has proved beneficial in alleviating 
the symptoms of psoriasis [1-3]. Neither 8-MOP nor UV-A 
irradiation separately is effective, This therapeutic regimen 
requires the proper synchronization of UV -A irradiation with 
oral intake of 8-MOP for activation, in which covalent binding 
of 8-MOP to the pyrimidine bases of nucleic acids of the cell 
occurs [4,5]. Except at very high doses long-wave irradiation 
alone does not sensitize the skin to produce prolonged erythema 
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[6]. It is not yet practical to measure drug concentration in the 
skin_ However, the sensitivity of the skin to UV-A irradiation 
in the presence of 8-MOP can provide a relative estimation of 
8-MOP levels in the skin over a given time course. At any given 
time a series of patches are irradiated with measured increments 
of radiant energy at a frequency which activates 8-MOP_ The 
minimal phototoxic dose (MPD) is t he amount of radiant 
energy measured in joules which just produces visible erythema_ 
We have been able to measure 8-MOP plasma concentrations 
of 4 ng/ ml [7]. We have simultaneously measured MPD's and 
8-MOP plasma concentrations at several times during the 8-hr 
period following drug ingestion in 20 psoriatic patients. We 
have analyzed the 8-MOP absorptive patterns for effect offood, 
absolute peak levels, time of peak levels, elinlination half life 
and correlation with skin sensitivity to irradiation, All studies 
were performed with the same dmg preparation, 8-MOP 
(Elder), that is currently the only drug available on the U.S. 
market, We have previously shown that random sampling of 
the 10 mg capsules of this preparation uniformly contain the 
specified quantity of 8-MOP [7]. Each individual has a unique 
absorptive pattern which correlates with the pattern of skin 
sensitivity to UV -A as determined by the MPD's. These pat-
terns have proved to be useful for determining whether thera-
peutic tlu-esholds have been achieved_ Knowledge of 8-MOP 
plasma level and simultaneous MPD over time can be useful in 
predicting skin response to a known plasma level of the drug. 
MATERIALS AND METHODS 
Patien.ts 
Twenty-two volunteers with severe psoriasis currently undergoing 
PUVA therapy were stuclied after informed consent had been obtained. 
The pa tients ranged in age from 26 to 72. Ten patients were males,. 12 
patients were females. Twenty patients were studied for the correlatIOn 
between skin photosensitivity and 8-MOP blood levels. T he degree of 
photosensitivity was determined by history of reactions to sunlight on 
a scale from I (fa irest skin) to III by the method of Wolff et al [~]. 
Eleven volunteers were of skin type III, 7 of skin type II and 2 of skm 
type 1. ALI patients were advised to fo llow their normal diet preceding 
a PUVA therapy session. Most patients ingested a small amount. of 
bland food with their 8-MOP capsules to offset the nausea-producmg 
effect of the drug. Four pat ients fasted for 10 111" preceding ingestion of 
. the drug. All patients ingested 8-MOP (Oxsoralen, Paul B. Elder Co. , 
Bryan, Ohio) in 10 mg capsules. Dosage levels ranged from .40 to .82 
mg of 8-MOP/ kg body mass with an average dosage of .62 mg/ kg (one 
exception is a pat ient with an extreme dosage at 1.77 mg/ kg) . 
Irradiation 
Twenty volunteers were irradiated beginning 2, 3, 4 and 6 hr a~ter 
ingestion of the 8-MOP. At each irradiation five patches each 4 cm of 
plaque-free skin on the buttocks, thigh or lower ba.ck .were exposed to 
several increments of UV-A irradiation. The irradIatIOn doses vaned 
from 2-28 joules/cm2 in the population_ The dosage for each patient 
Abbreviat ions: 
AUC: a rea under the curve 
HPLC: high pressure liquid chromatography 
ID: in ternal diameter 
LMPD: lowest MPD 
8-MOP: 8 methoxypsoralen, methoxsalen 
MPD: minimal phototoxic dose 
PUV A: 8- MOP and UV -A photochemotherapy 
UV-A: long-wave ultraviolet light 
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FIG 1. Chemical structures of psoralen, 8-methoxypsoralen (8-
MOP) and ammidin. 
was chosen on the basis of skin type and current treatment levels so as 
to assure erythema in at least the highest energy patch. The dose 
increments increased semi-logarithmically. For example, one typical 
patient who had type III skin and was receiving 12 J /cm2 for psoriasis 
treatment was phototested with 7, 10, 14, 19 and 25 J/cm". All other 
areas of the body were shielded from irradiation. We used a bank of 8 
fluorescent lamps (Sylvania FR72TI2). The output of the lamp was 
constant during each session as monitored at 5-min intervals with the 
International Light modelIL441 UV-A detector (reading at 365 nm). 
Output decreased slightly from 13 to 10 milliwatts/cm2 with aging of 
the lamps. Duration of irradiation and distance from the lamps were 
adjusted to produce the desired energy exposure. Erythematous re-
sponse was judged at 48 hr after exposure. 
Materials 
All solvents employed for the extraction and chromatographic anal-
yses were analytical reagent grade. The 8-MOP used as external stan-
dard in the HPLC analysis was obtained from Sigma Chemical Co., St. 
Louis, Missouri and was recrystallized twice from methanol. Ammidin, 
a psoralen derivative (Fig 1), was employed as internal standard and 
external standard in each analysis and was a gift provided by AB Draco, 
Lund, Sweden. 
Extraction 
Blood samples were obtained at 1, 2, 3, 4, 6, and 8 hr after ingestion 
of the 8-MOP. All blood samples were obtained in heparinized tubes 
and the plasma was separated immediately. The extraction procedure 
was modified in this laboratory by Ljunggren et al [7] from a technique 
originally described by Puglisi, de Silva, and Meyer [9]. All glassware 
used in the extraction was treated with a 2% solution of polyethylene 
glycol in chloroform for 5 min and was heated in a drying oven at 150°C 
fol' 60 min. To 1 ml samples of plasma were added: 200 ng of ammidin 
as internal standard and 2.5 ml of aIM borate buffer (pH 9.0). Samples 
were then extracted with 8 ml of benzene at room temperature on a 
reciprocating shaker for 20 min. The samples were then centrifuged at 
5°C for 15 min. The organic layer was removed and evaporated at 45°C 
under dry nitrogen. T he residue was redissolved for chromatographic 
analysis in 200 III of a 95::5 mixture of methylene chloride:acetonitrile. 
Chromatographic Procedure 
We used a high-pressure liquid chromatograph (Altex, model 330, 
Berkeley, CAl eq uipped with an Altex 254 nm U.V. detector. The 
stationary phase in the system was a microparticulate silica gel column 
(Partisil 10, 1.D. 4.6 mm, length 250 mm, Whatman Inc., Clifton, New 
Jersey). The mobile phase was the 95::5 mixture of methylene chlo-
ride:acetonitrile. The flow rate was 2.2 ml/ min. Best results were 
obtained with pressures below 2,000 psi. A 20 iJl sample of the redis-
solved sample was injected onto the column. 
. Calculations 
Calculations of 8-MOP plasma concentrations as previously de-
scribed [7] were based on the relative peak heights from the chromat-
ogram: of the plasma 8-MOP and the ammidin internal standard, and 
of 20 ng of 8-MOP and ammidin as external sthndard. Calculations al'e 
based on the formula: 
8-MOP (ng/inl) 
= plasma 
External Std. Ammidin x Patient 8-MOP x 200 
Internal Std. Ammidin External Std. 8-MOP 
peak heights peak heights 
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The internal standard accounted for any loss of the patient's plasma 
8-MOP during the extraction procedure. The validity of th is approach 
was tested with known amounts of 8-MOP and ammidin that were 
added to control plasma samples [7]. 
Elimination half Lives of 8-MOP time courses were calculated by the 
method of least sqUal'es linear regression analysis using a Hewlett-
Packard computer (model 9810A) and plotter (model 9862A). 
Results and Discussion 
Effect of Food Intake 
A total of 31 8-MOP time courses were obtained in 22 
volunteers (Table I). Twenty-one patients were studied under 
nonfasting conditions. Two of these patients demonstrated un-
usual biphasic patterns (patients 8 and 13, Fig 2). When these 
2 individuals were studied under fasting conditions, both ab-
sorptive patterns followed the typical monophasic time course 
with greater peak levels of the drug. Two additional patients 
under nonfasting conditions also demonstrated less pronounced 
biphasic patterns (patients 18 and 19). We wished to know the 
variability of absorptive patterns from day to day in an individ-
ual under fasting conditions. Two patients' 8-MOP absorptive 
patterns were studied under fasting conditions on four succes-
sive occasions (patients 15 and 22). Both patients demonstmted 
consistent 8-MOP patterns (Fig 3). There was 1 hr variation in 
time of peak levels, 0.2 hr variation in half life and a 135-206 
ng/ml and a 108-217 ng/ml variation in peak plasma levels 
respectively. Wagner et al [10] have shown that low and/or 
delayed 8-MOP peak plasma levels may be associated with poor 
response to PUVA therapy. A consistent time course would be 
desirable in order to insure a favorable therapeutic response. 
Though food intake may enhance bioavailability while not 
affecting elimination rates [11], it may alter factors leading to 
consistent absorption, metabolism and distribution of the drug. 
Food intake is often desirable with 8-MOP administration in 
order to counter the nausea associated with ingestion of the 
drug. As a result of this study we now recommend that mini-
mum food intake and consistent dietary habits be maintained. 
Oral Dosage 
In our population of 22 patients oral dosage ranged from .40 
to .82 mg/kg (with one exception of 1.77 mg/kg). The recom-
mended dosage from the U.S. cooperative clinical trial protocol 
is .60 mg/kg. The peak 8-MOP plasma concentrations varied 
from 13 ng/ml to 782 ng/ml. Our results (Table 1, Fig 4) indicate 
that there is no correlation between oral dosage as adjusted for 
body mass and peak levels of the drug. This is in agreement 
with the work of Wagner et al [10], who could not account for 
variations in the area under the curve (AUC) in patients in-
gesting similar amounts of drug. The oral dose of 8-MOP cannot 
be used to predict what plasma levels of the drug will be 
achieved. 
Elimination Rates 
Elimination rates obeyed fU'st-order kinetics. All half lives 
(Table 1) were calculated from either 3, 4, or 5 data points from 
each patient's time course. Of the 21 volunteers studied under 
nonfasting conditions only 16 patients had sufficient numbers 
of significant data points (8-MOP concentration >4 ng/ml) for 
evaluation of elimination rates. Of these 16, two were excluded 
on the basis of an inadequate correlation coefficient (P> 0.10), 
and one failed the 95% confidence limit (z=1.96) for a normal 
population. The values of the 13 valid half lives ranged from 1.3 
to 2.8 hr with an average of 2.1 ± 0.5 hr. Four volunteers were 
studied under fasting conditions. Half lives ranged from 1.3 to 
2.3 hr with an average of 1.7 ± 0.3 hr. Our results confil"m the 
conclusion of Busch et al [12] that 8-MOP elimination follows 
fU'st-order kinetics. Little difference in half lives was noted 
between fasting and nonfasting conditions, in agreement with 
Ehrsson et al [11]. The time courses were evaluated assuming 
a monofunctional first-order elimination rate. Recent work in 
our laboratory on several patients who exhibited high peak 
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TABLE 1. 8-MOP plasma levels (fasting and nonfasting), elimination rate half-lives, and simultaneous shin response time course studies 
(non-fasting) with K values 
NONFASTING 
1 hr 2 hr 3 hr 4 hr 6 hr S hr 
Shin ---
Pt Dose type (S-MOP) (8-MOP) MPD K , (8-MOP) MPD K" (S-MOP) MPD K. (8-MOP) MPD KG (S-MOP) tl / '2 K 
1 .68 II 4 6 >22 
-
11 >22 
- 13 >22 - 4 >22 - 0 - -
2 .76 III 13 14 >27 - 8 >27 - 8 >27 - 4 >27 - 0 - -
3 .57 II 4 5 >25 
- 8 >25 - 16 >25 - 10 >25 - 4 2.1 -
4 .60 III 16 28 >26 
-
23 >26 
- 16 >26 - 8 >26 - 0 2.0 -
5 .60 II 23 30 11 8.9 41 7 7.5 '48 11 8.3 17 11 7.9 39 - 8.2 ± 0.6t 
6 .40 II '68 40 11 
- 28 11 - 24 8 8.8 14 15 9.0 18 2.8 8.9 ± 0.2t 
7 .64 III 4 7 26 6.3 68 13 10.8 '79 13 11.2 22 13 7.9 13 (1.5) 9.0 ± 2.3 
8 .53 I 49 22 >13 
-
8 >13 
- 38 13 9.3 '85 6 8.0 69 - 8.6 ± 0.9 
9 .63 III 24 57 13 11.0 73 9 10.2 '103 13 10.2 29 23 9.5 13 1.3 10.4 ± 0.6t 
10 .69 III 0 19 >28 
-
110 >28 - '111 17 13.3 77 17 12.3 20 (1.6) 12.8 ± 0.7 
11 .73 I1I 91 121 15 13.0 '129 12 12.1 109 15 12.7 39 19 10.8 27 2.0 12.1 ± 1.0 
12 .74 II 9 '137 9 10.8 120 9 10.5 89 12 11.2 41 12 7.7 19 1.9 10.1 ± 1.6 
13 .50 - 53 '144 
- -
45 
- - 15 - - 87 - - - - -
14 .79 I 20 '163 5 8.2 160 5 8.2 76 8 9.0 25 11 7.7 8 1.4 8.3 ± 0.5 
15 .69 I1I 84 140 7 9.6 '167 7 10.0 113 7 9.2 68 10 9.7 47 2.8 9.6 ± 0.3 
16 .48 II ' 171 137 5 
-
134 3 5.6 93 3 5.4 43 8 9.4 32 2.4 6.8 ± 2.3t 
17 .48 III 48 '179 12 12.9 102 12 ll.5 47 15 10.4 37 15 9.8 13 1.7 11.1 ± 1.4 
18 .58 III 172 '200 7 10.3 139 14 13.0 147 14 13.2 104 14 12.3 70 &3.7 12.2 ± 1.3 
19 .82 III '222 133 11 13.0 147 15 13.2 180 19 14.7 90 25 15.8 57 2.4 14.2 ± 1.3t 
20 .61 II 140 '347 15 15.8 157 15 13.7 100 18 13.3 5 hrs 27 18 9.5 25 1.7 13.1 ± 2.6 
21 1.77 III - 187 
- - 562 13 16.3 571 10 15.3 '782 567 13 15.6 314 2.3 15.7 ± 0.5t 
FASTING 
13 .50 80 '174 88 50 17 11 1.5 
8 .53 110 '178 142 72 53 27 2.3 
15 .69 117 '206 121 71 23 14 1.5 
15 .69 29 139 '145 90 28 JO 1.3 
15 .69 76 123 '148 91 33 16 1.5 
15 .69 32 126 '135 102 38 J6 1.5 
22 .64 63 '109 63 41 17 12 1.9 
22 .64 167 ' 180 134 88 37 25 2.0 
22 .64 '217 213 135 66 37 17 1.8 
22 .64 81 '158 128 76 43 18 1.8 
Oral dose 8-MOP m mg/ kg body mass. (8-MOP) mdlcates 8-MOP plasma concentration in ng/ ml. MPD is the mini mal phototoxic dose expressed in Joules .. '>" 
indicates no erythema at the highest energy level of irradiation. t' l' calculated by least squares linear regression when 3 or more s ignificant data points available: P 
::s 0.10. "0" indicates t,I' values with P > 0.10. K values defined in text. 
* indicates peak 8-MOP p lasma concentration. 
t K values calcu lated from shifted curves such that peak 8-MOP value corresponds to first LMPD. 
& indicates t,I' value with failure of 95% confidence limit (Z = 1.96) for a normal population distribution. 
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FIG 2. Biphasic time course studies in 2 PUV A patients under 
nonfasting conditions and monophasic patterns in the same patients 
under fasting conditions. 
levels of 8-MOP >(350 ng/ml) suggests that elimination rates 
may be bifunctional with an early, rapid (alpha) phase half life 
and a late, slow (beta) phase half life. 
Variability of Patterns 
There were considerable differences in the patterns of the 
tiIne courses_ In the time-course patterns for 2 individuals 
shown in Fig 5 the dose and elimination rates were similar 
though the plasma patterns are representative of the 2 ex-
tremes. Differences in absorption, metabolism and distribution 
of the drug must be largely responsible for the va.riations. 
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FIG 3. Repeated time course studies in 2 patients under fasting 
conditions. Each individual displayed similar patterns of 8-MOP plasma 
levels. 
Ehrsson et al [11] found that zero order absorption rate con-
stants varied from 0_501 to 2_288 hr- I in 5 nonfasting individuals 
ingesting 40 mg of 8-MOP_ Busch et al [12] found extremely 
rapid absorption of 14C labeled 8-MOP with the rapid appear-
ance of metabolites in the plasma of 5 individuals. They also 
found that oral administration of crystalline drug (as in our 
study) resulted in significantly greater fecal elimination of the 
unaltered drug than oral administration of a dissolved formu-
lation of the drug. Kreuter and Higuchi [13] also found in-
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creased bioavailability in dogs and rats when 8-MOP was ad-
ministered in the dissolved state. A significant factor accounting 
for variations in absorptive patterns may be individual variation 
in the ability to dissolve and absorb the crystalline 8-MOP 
preparations currently available. A significant difference in 
bioavailability of 2 manufactW'ers' preparations was previously 
demonstrated in this laboratory [7]. No studies have yet been 
published documenting inter-individual differences of metabo-
lism and distribution of the drug in man, though studies on 
metabolic products in man [12] and extent of binding to plasma 
proteins in man [12,14] have been published. 
8-MOP Plasma Concentration and Shin Response 
Twenty patients wel"e irradiated to detel"mine minimum pho-
totoxic dose (MPD) while 8-MOP plasma concentrations were 
monitored. FoW' patients (pts. 1-4) with peak 8-MOP concen-
trations below 30 ng/ml demonstrated no erythema at any of 
the energy levels irradiated. Patients 5 and 6 with peak 8-MOP 
levels of 48 and 68 ng/ml respectively did demonstrate ery-
thema at all times of irradiation. This suggests that a peak level 
of 8-MOP between 30 and 50 ng/ml is required to produce an 
erythematous response. Such a threshold might vary for each 
individual as a function of skin type, degree of pigmentation 
and the extent of metabolism and distribution of the drug. 
All 4 patients were maintained on an oral dosage of 8-MOP 
that is adequate by cW'rent standards. These patients did not 
respond to sensitizing doses of irradiation, and they gave a 
history of poor response to therapy. Low plasma levels may be 
the norm in these individuals and the reason for their poor 
therapeutic response. Wagner et a1 [10] also found lower-than-
average maximum 8-MOP plasma levels and low areas under 
the cW've (AUC) values in PUVA problem cases with psoriasis . 
The 8-MOP threshold for an erythematous response may ap-
proximate the 8-MOP therapeutic threshold. 
Thirteen patients with peak 8-MOP levels between 48 and 
347 ng/ml demonstrated erythema at all times of irradiation. 
Patients 8 and 10 did not produce erythema at the highest 
levels of irradiation at 2 and 3 hr after ingestion. Patient 21 did 
produce erythema at 3, 4, and 6 hr, but is excluded from a 
statistical summary of the data because of the unusual oral 
dose. The lowest average MPD and the greatest number of 
LMPD's for these 13 patients occw' at 3 hoW's after ingestion 
(Table II). The peak average 8-MOP plasma concentration 
occurs at 2 hr after ingestion. The time of greatest skin sensi-
tivity may reflect the time of greatest skin concentration of the 
drug. The lowest average MPD and the greatest number of 
LMPD's oCCW' 1 hr later than the peak average 8-MOP plasma 
concentration. The average MPD at 2 iu is just slightly greater 
than at 3 hr. These values suggest a 0 to 1 hI" delay in 8-MOP 
plasma-to-skin equilibrium. 
Of the 16 patients who demonstrated erythema, 10 demon-
strated simultaneous peak 8-MOP plasma concentration and at 
least one LMPD. Eight patients demonstrated maximum skin 
sensitivity 1 hr after peak 8-MOP levels. Patients 16 and 6 with 
peak 8-MOP concentrations at 1 hr after ingestion demon-
$trated 2 and 3 hr respective delays in maximum skin sensitivity. 
In some individuals plasma-to-skin equilibration of 8-MOP may 
be significantly slower than 8-MOP absorption. Three patients 
(pts. 5, 9, and 12) demonstrated LMPD's which preceded peak 
8-MOP concentration by 1 hr. Maximum 8-MOP plasma con-
centration occw's at 4 or 5 hr in these patients. Significant 
TABLE II. Composite time course of 13 patients" 
1 h,. 2 h,. 3h,. 4 h,. 6/1,. 8 h,. 
8-MOP average ± S.D. 83 ± 72 · 130 ± 89 113 ± 46 93 ± 42 43 ± 28 29 ±. 19 
MPD average ± S.D. 11 ± 6 10 ± 4 12 ± 5 15 ± 5 
number of LMPD's 7 10 4 1 
" Average values of the data from 13 patients with complete drug level and skin response time courses. 
May 1982 
plasma concentrations occur at 2, 3, and 4 Ill". When slow, 
steady absorption of 8-MOP occurs over a period of several 
hours plasma-to-skin equilibration may precede maximum 
plasma concentration of the drug. Our studies have not excluded 
the possibility of maximum skin sensitivity at 1 hl" after inges-
tion. 
Relation of Plasma Levels to Shin Response 
A general trend in all the time courses is the inverse relation 
between 8-MOP plasma levels and MPD's. The cumulative 
data from the 13 patients with complete time courses (Table 
II) show that the 8-MOP level falls as the MPD rises. With 
adjustment for delays in distribution the converse also appears 
to be true. Swan beck et al [15] described a negative linear 
correlation between the log of the 8-MOP plasma concentration 
and the MPD in the cumulative data from 5 volunteers. Because 
of extensive variation in the skin responses of our patient 
population we have examined each patient on an individual 
basis. We have found that the loge (MPD) may be inversely 
proportional to the loge (8-MOP). The product of these 2 
parameters yie~ds a constant K, at time t after ingestion and an 
average value K over all times (Table I): 
1 
loge MPD ::::: -:------:-:=-=-=-=-=::-:---loge (8-MOP)plusmu 
constant K = loge MPD X loge (8-MOP)plusmu 
For the 10 patients with simultaneous peak 8-MOP concen-
trations and LMPD's this calculation is straightforward. In 6 
cases the time course curves have been shifted such that the 
peak.8-MOP levels correspond to the earliest LMPD. In this 
way we account for variations in the handling of the drug. The 
results of this manipulation also suggest a correlation. The 
value of K varies from individual to individual. Its value may 
be influenced by factors affecting absorption, distribution and 
metabolism of the drug and by skin type and degree of skin 
pigmentation. The average value of K is greater for darker skin 
types: K values averaged 11.9 for skin type III patients, 9.4 for 
skin type II patients and 8.4 for skin type I patients. The value 
of K for each individual might be useful in predicting skin 
response to irradiation given a known plasma concentration of 
8-MOP. 
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